| DC8041 |
MK-0941
Featured
|
MK-0941 is a novel Glucokinase activator (GKA) |
|
| DC9398 |
MK-0974 |
MK-0974(Telcagepant) is a highly potent, selective, and orally bioavailable CGRP receptor antagonist with Ki values of 0.77 nM and 1.2 nM for human and rhesus CGRP receptors respectively; displays >1500-fold lower affinity for the canine and rat receptors |
|
| DC21293 |
MK-1 |
MK1 is a small molecule inducer of megakaryopoiesis (EC90=750 nM) that induces the differentiation of common myeloid progenitors (CMP) to megakaryocytes, does not adversely affect erythrocyte differentiation. |
|
| DC9966 |
MK-1064
Featured
|
MK-1064 is a selective orexin 2 receptor antagonist (2-SORA) for the research of insomnia. |
|
| DC1070 |
MK-1775(AZD-1775,Adavosertib)
Featured
|
MK-1775 is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM. |
|
| DC23650 |
MK-1832 |
MK-1832 is a potent, selective Kv1.5 inhibitor with IC50 of 86 nM, exhibits improved selectivity for IKur over IKs (>3000-fold) compares with MK-0448 (70-fold), also exhibits an improved preclinical pharmacokinetic profile.. |
|
| DC26086 |
MK-1925 |
MK-1925 is a selective, orally active, brain-penetrant opioid receptor-like 1 (ORL1. |
|
| DC21296 |
MK-204 |
MK-204 is a potent, selective AKR1B10 inhibitor with IC50 of 80 nM, shows high selective (270-fold) over AKR1B1. |
|
| DC23099 |
MK-2048 |
MK-2048 is a potent inhibitor of HIV-1 integrase (IN) and IN mutant R263K with IC50 of 2.6 nM and 1.5 nM, respectively. |
|
| DC7465 |
MK-2206 2HCl
Featured
|
MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2. |
|
| DC9607 |
MK-2894 |
MK-2894 is a highly potent and selective second generation EP4 antagonist.
|
|
| DC24121 |
MK2-IN-1 |
MK2-IN-1 is a potent, selecitve, non-ATP competitive MAPKAPK2(MK2) inhibitor with IC50 of 0.11 uM. |
|
| DC24120 |
MK2-IN-1 hydrochloride
Featured
|
MK2-IN-1 is a potent, selecitve, non-ATP competitive MAPKAPK2(MK2) inhibitor with IC50 of 0.11 uM. |
|
| DC7585 |
Omarigliptin
Featured
|
MK-3102 (MSD) is a novel DPP-4 Inhibitor, which improves glycaemic control with low risk of symptomatic hypoglycaemia. |
|
| DC9397 |
MK-3207 (Hydrochloride) |
MK-3207 is a potent and orally bioavailable CGRP receptor antagonist (IC50= 0.12 nM; Ki value= 0.024 nM); highly selective versus human AM1, AM2, CTR, and AMY3.
|
|
| DC21297 |
MK-3281 |
MK-3281 is a potent and orally bioavailable inhibitor of HCV NS5B polymerase with IC50 of 6 nM. |
|
| DC7646 |
MK3697 |
MK-3697 is a third insomnia drug, currently being developed by Merck. MK-3697 is a potent and selective Orexin receptor antagonist with Ki = 0.95 nM. |
|
| DC22731 |
MK-3901 |
MK-3901 is a potent, selective, orally active P2X3 antagonist with IC50 of 21 nM. |
|
| DC11405 |
MK-3903
Featured
|
MK-3903 is a potent and selective AMP-activated protein kinase (AMPK) activator with an EC50 of 8 nM.
generation of catalytically active enzyme. |
|
| DC20454 |
MK-4074 sodium salt |
MK-4074 is a potent, liver-specific, orally active inhibitor of acetyl-CoA carboxylase ACC1 and ACC2 with IC50 of ~3 nM. |
|
| DC21286 |
MK-4074 |
MK-4074 is a potent, liver-specific, orally active inhibitor of acetyl-CoA carboxylase ACC1 and ACC2 with IC50 of ~3 nM. |
|
| DC9707 |
MK-4101
Featured
|
MK-4101 is a potent SMO Inhibitor of the Hedgehog Pathway, highly active against Medulloblastoma and Basal Cell Carcinoma. |
|
| DC4179 |
Niraparib(MK4827) free base
Featured
|
MK-4827 is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. |
|
| DC9862 |
Niraparib(MK4827) hydrochloride
Featured
|
MK-4827 is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. |
|
| DC9576 |
Niraparib tosylate
Featured
|
MK-4827(Niraparib) tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM; with great activity in cancer cells with mutant BRCA-1 and BRCA-2; >330-fold selective against PARP3, V-PARP and Tank1.
|
|
| DC9201 |
Grazoprevir(MK-5172)
Featured
|
MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development. |
.png)
|
| DC7729 |
Grazoprevir
Featured
|
MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development. |
|
| DC9279 |
MK-571
Featured
|
MK-571 is a selective, orally active CysLT1 receptor antagonist. |
|
| DC9448 |
MK591 |
MK591(Quiflapon sodium) is a selective and specific 5-Lipoxygenase-activating protein (FLAP) inhibitor. |
|
| DC7745 |
Filorexant(mk-6096)
Featured
|
MK-6096 is an orally bioavailable potent and selective reversible antagonist of OX(1)R and OX(2)R currently in clinical development for insomnia. |
|
